Physician profile
Jamie M Andre
NPI 1962665638
$7,726.55
in general payments reported to CMS, 2019-2025
24 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $152 · 2021: $1,432 · 2022: $1,349 · 2023: $1,499 · 2024: $1,642 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,295 · Education: $56.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,295.08 |
| Education | $56.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,347.12 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $1,321.43 | 2021-2025 | |
| Vifor Pharma, INC. | $1,053.72 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $666.03 | 2021-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $536.88 | 2020-2025 | Acthar |
| Fresenius USA Marketing, INC. | $523.18 | 2020-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $376.94 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $327.01 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $295.66 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Horizon Therapeutics Plc | $239.81 | 2020-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $182.07 | 2023-2025 | Lupkynis |
| Akebia Therapeutics INC | $165.40 | 2019-2024 | Vafseo |
| Amag Pharmaceuticals, INC. | $124.95 | 2019 | |
| Baxter Healthcare | $118.21 | 2022-2024 | Renal - Pd |
| Lilly USA, LLC | $88.32 | 2021-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $87.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.03 | 2024 | Jardiance |
| Novo Nordisk INC | $47.69 | 2021-2023 | Ozempic |
| Travere Therapeutics, INC. | $40.57 | 2025 | |
| Ani Pharmaceuticals, INC. | $31.90 | 2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $22.90 | 2024 | Aveir |
| Glaxosmithkline, LLC. | $20.33 | 2022 | |
| Pfizer INC. | $15.87 | 2023 | |
| Alkermes, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Andre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.